ライフサイエンスコーパス: disappointing

1 factor control in clinical practice has been disappointing.

2 for acute myeloid leukemia (AML) has proved disappointing.

3 cines in phase IIa/b clinical trials remains disappointing.

4 rods and found that this approach is rather disappointing.

5 ing genes for multifactorial stroke has been disappointing.

6 whose cause is unclear and treatment remains disappointing.

7 compounds in human clinical trials has been disappointing.

8 to acetylcholinesterase inhibitors is often disappointing.

9 presenting at an advanced stage is therefore disappointing.

10 mpts to solve this problem have been largely disappointing.

11 alone in this patient group has proven to be disappointing.

12 ere developed, but clinical trials have been disappointing.

13 nfarction (AMI) for patient benefit has been disappointing.

14 and the replication among studies is rather disappointing.

15 unmodified antisense RNAs has generally been disappointing.

16 d in patients with myeloma, and results were disappointing.

17 the outcome of cell transplantation remains disappointing.

18 r peripheral nerve repair in humans is often disappointing.

19 y-dwelling adults, which, to date, have been disappointing.

20 However, clinical studies have so far been disappointing.

21 hat adherence to health education advice was disappointing.

22 nism, and VEGF delivery to patients has been disappointing.

23 on anticoagulation duration has largely been disappointing.

24 thic pain in small fibre neuropathy is often disappointing.

25 s with known proangiogenic factors have been disappointing.

26 sis to provide improved resolution have been disappointing.

27 ion to the diagnostic armamentarium has been disappointing.

28 us clinical trials with this agent have been disappointing.

29 t of fulminant colitis in children have been disappointing.

30 V squamous cell head and neck cancer remains disappointing.

31 urodegenerative diseases has been meager and disappointing.

32 overall survival with this approach has been disappointing.

33 in diseases where conventional DLI has been disappointing.

34 human clinical trials have, in general, been disappointing.

35 e clinical trials (oral administration) were disappointing.

36 tients with congenital corneal opacities are disappointing.

37 ment of bacterial vaginosis in pregnancy are disappointing.

38 pancreatography pancreatitis (ERCP) has been disappointing.

39 odies and nuclear medicine imaging have been disappointing.

40 ical effectiveness of immunotherapy has been disappointing.

41 ine therapy in the adjuvant setting has been disappointing.

42 ces and antiarrhythmic drug therapy has been disappointing.

43 ablation therapy for many patients has been disappointing.

44 onists in congestive heart failure have been disappointing.

45 IDs) in the treatment of AD have so far been disappointing.

46 t, is common and the 5-year survival rate is disappointing.

47 However, results have been disappointing.

48 improved clinical outcomes has been largely disappointing.

49 nventional immunosuppressive agents has been disappointing.

50 ividual genetic abnormalities have also been disappointing.

51 patients with Parkinson's disease have been disappointing.

52 cells for therapeutic applications have been disappointing.

53 infarction, and hemorrhagic shock-have been disappointing.

54 but the results for larger tumors have been disappointing.

55 The results of these trials have been disappointing.

56 e results of islet transplantation have been disappointing.

57 complex traits has been difficult and often disappointing.

58 SWL) for lower calyceal stones are generally disappointing.

59 ent of autoimmune disease in humans has been disappointing.

60 g in-stent restenosis have been consistently disappointing.

61 rts, but our results have in some cases been disappointing.

62 es, the overall impact on pathology has been disappointing.

63 s to identify the underlying genes have been disappointing.

64 eous sarcoidosis is easy, but the therapy is disappointing.

65 ts of therapy with D-penicillamine have been disappointing.

66 fusion to clinical practice has to date been disappointing.

67 ancers to immune therapies has thus far been disappointing.

68 anoma, their use in ocular variants has been disappointing.

69 trial results with HDACi have thus far been disappointing.

70 istors' power amplification ability has been disappointing.

71 -D monoclonal antibodies have been, at best, disappointing.

72 ion of in vitro to in vivo findings is often disappointing.

73 antioxidants have, however, been clinically disappointing.

74 ceutical, but subsequent investigations were disappointing.

75 Pharmacological treatments were disappointing.

76 rates to therapeutic clinical trials remain disappointing.

77 sults with anti-angiogenic therapy have been disappointing.

78 , gains from second-line therapies have been disappointing.

79 sults of clinical trials have generally been disappointing.

80 cardioversion in restoring sinus rhythm was disappointing.

81 d some success, but outcomes post-ITx remain disappointing.

82 romising results, trials in humans have been disappointing.

83 vasculitis and myasthenia gravis were rather disappointing.

84 cancer antigen 125 as an antigen, have been disappointing.

85 inues, the clinical return has thus far been disappointing.

86 New treatments of refractory GERD have been disappointing.

87 om a generation ago, is generally still very disappointing.

88 how brain processes cause consciousness are disappointing.

89 ght to drive tumor growth, results have been disappointing.

90 Overall 5-year patient survival was a disappointing 35%.

91 s of sleep-disordered breathing have shown a disappointing ability to predict important consequences

92 ibition using sulfonylurea agents has proved disappointing, although agents acting on its pore appear

93 vitamin E supplements and cataract have been disappointing and are not yet available for selenium.

94 s to identify genetic variants have produced disappointing and contradictory results.

95 th oncogenic RAS signaling have been largely disappointing and have not resulted in meaningful clinic

96 py to inhaled corticosteroids, they are also disappointing and less effective than long-acting beta(2

97 Current treatments are disappointing and often have little beneficial effect.

98 immunosuppressive drugs has been relatively disappointing and there have been few efforts in definin

99 , clinical activity in solid tumors has been disappointing and toxicity has been a serious concern.

100 for persistent atrial fibrillation (AF) are disappointing and usually do not exceed 60%.

101 approaches to Alzheimer disease (AD) remain disappointing and, hence, there is an urgent need for ef

102 models are still widely used, but have been disappointing, and development of genetic models has giv

103 ept in the treatment of sarcoidosis has been disappointing, and may actually cause the disease.

104 ed epithelial ovarian carcinoma (EOC) remain disappointing, and the development of more effective pri

105 ted therapy for solid tumors has so far been disappointing, and the reasons for this poor response in

106 greater clinical impact than have the so far disappointing antisense endeavors.

107 tely, results from clinical trials have been disappointing as off-target effects and toxicities have

108 sis," Sriram and Steiner(1) wrote, "The most disappointing aspect of EAE [experimental allergic encep

109 ials of ARIs on diabetic neuropathy appeared disappointing because of either 1) their inadequate desi

110 of HCV treatment in this population has been disappointing because of low rates of treatment initiati

111 iences with EGFR kinase inhibitors have been disappointing, because resistance is common and tumors e

112 idual hormone/mediator have yielded somewhat disappointing body weight changes, often leading to the

113 candidate vaccine and microbicide have been disappointing, both for want of efficacy and concerns ab

114 an, interferon gamma, and relaxin) have been disappointing but new strategies against fibrosis based

115 icide candidates in efficacy trials has been disappointing, but next-generation concepts now in or ap

116 ediator antagonists tested in COPD have been disappointing, but of CXCR2 antagonists that block pulmo

117 Considering the disappointing clinical activity of HSP90 inhibitors in o

118 targets and lead to improvement of the still disappointing clinical outcome of these patients.

119 fusion of red blood cells has been linked to disappointing clinical outcomes in the critically ill, b

120 eptor (EGFR)-targeted therapies have yielded disappointing clinical results in treatment of this canc

121 E) to prevent lung cancer have produced only disappointing clinical results to date.

122 vered, perhaps an explanation for the so-far disappointing clinical translation to the prevention and

123 ouraging experimental work has led so far to disappointing clinical trials and the identification of

124 ta in humans with one agent (infliximab) but disappointing controlled data from another (etanercept).

125 c strategies that will improve the currently disappointing cure rate (approximately 25-40%) of this g

126 myocardial infarction, have provided largely disappointing data.

127 hrenia have yielded both promising leads and disappointing dead ends, indicating the multifactored an

128 geted inhibition of EGFR has been clinically disappointing, demonstrating an innate ability for GBM t

129 autoimmune diseases have often been notably disappointing despite many claims for linkages.

130 w antibacterial agents has been particularly disappointing, despite a plethora of potential targets,

131 poptotic receptor agonists (PARAs) have been disappointing, despite compelling preclinical efficacy w

132 ng antioxidant supplements have been equally disappointing, despite the clear benefits of a healthy d

133 alysts, their enzymatic performance has been disappointing due to low reaction rates.

134 nisms for exercise hyperaemia are especially disappointing due to the essentially concurrent discover

135 ng program implementation, results have been disappointing, e.g., only 7% of candidates passing the p

136 ith two devices have been stopped because of disappointing early results.

137 n clinical trials, MEK inhibitors have shown disappointing efficacy in mutant NRAS patients, the reas

138 s for solid-organ transplantation have shown disappointing efficacy in the prevention of chronic allo

139 Disappointing efficacy of 11betaHSD1 inhibitors in phase

140 The disappointing efficacy of blood-stage malaria vaccines m

141 ain a better understanding of the clinically disappointing EGFR-targeted therapies for GBM, we invest

142 of the tests with glans swab specimens were disappointing except for those from patients with sympto

143 ecific antisense have resulted in an overall disappointing experience.

144 nagement strategies, highlighting the rather disappointing experiences with mechanical and systemic d

145 sharp contrast to the fit-to-cohort effect, disappointing findings to date, and limited reproducibil

146 ting vasculature may, in part, explain these disappointing findings.

147 rvival and overall survival, however, remain disappointing for children with metastatic RMS at diagno

148 However, blockade of EGFR is therapeutically disappointing for gliomas with PTEN deletion.

149 neic stem cell transplantation (SCT) but are disappointing for other diseases.

150 Nothing is more disappointing for patients than when a promising new tre

151 ise as a thermal material, results have been disappointing for practical thermal systems and applicat

152 initial clinical trials in humans have been disappointing, highlighting a need to optimize their imm

153 Despite a long disappointing history of human trials with neurotrophins

154 this burgeoning literature has thus far been disappointing, however, leaving open the question of whi

155 Effectiveness is then often disappointing in 'real life' conditions.

156 t in the context of atherosclerosis has been disappointing in clinical studies.

157 idual neurotrophic factors (NTF) have proved disappointing in clinical trials for neuronal repair and

158 gh increasing landscape complexity can prove disappointing in fields with low soil services or in int

159 Conversely, CBT has been relatively disappointing in follicular lymphoma and diffuse large B

160 l in a subset of patients with PPH, has been disappointing in HIV-associated pulmonary hypertension a

161 xpensive and their immunogenicity has proven disappointing in human clinical trials, we have been exp

162 disease and even promising agents have been disappointing in large-scale clinical trials.

163 Calcium antagonists have proved disappointing in long-term congestive heart failure (CHF

164 n animal models of ALS, but have been proven disappointing in part because effective targets have not

165 However, clinical trials have been disappointing in part to dose-limiting hypercalcemia.

166 onic laryngitis, cough, and asthma have been disappointing in showing benefit of acid suppressive the

167 other hand, offer safety but have often been disappointing in terms of efficiency of nuclear delivery

168 rength composite material, it exhibits quite disappointing in terms of modulus or strength.

169 chemical compounds-for other purposes-proved disappointing in tests against Ebola virus (EBOV) infect

170 me-wide association studies (GWAS) have been disappointing in the inability of investigators to use t

171 bal response to COVID-19 has been uneven and disappointing in the vast majority of countries.

172 mphoteric vectorization efforts proved to be disappointing in this series, aminoglycosidic and polyca

173 adder instillation of antibiotics has proved disappointing in treating UTI, likely due to the failure

174 Stimulation treatments have been disappointing in vegetative state but occasionally impro

175 ognosis, particularly in advanced stages, is disappointing largely due to the resistance to conventio

176 the clinical efficacy of gene therapies were disappointing, largely because the available gene-transf

177 nts however, overall 5-year survival remains disappointing: less than 25% of patients live for 5 year

178 ) fusion F glycoprotein previously exhibited disappointing levels of RSV F immunogenicity and genetic

179 L tyrosine kinase inhibitors (TKIs) has been disappointing, often resulting in short remissions typif

180 This past year has proved to be a relatively disappointing one for the development of agents that cou

181 inical trials into these therapies have been disappointing or conflicting.

182 mor necrosis factor-alpha activity have been disappointing, or of unproven benefit at best.

183 ssays, but with a precision of only 0.92%, a disappointing outcome that led to an examination of the

184 organic solar cells, although with a rather disappointing outcome to date in terms of efficiencies.

185 This disappointing outcome was traced to unfavorable pharmaco

186 rtant reasons are likely to account for this disappointing outcome, including failure to appreciate d

187 lection using drug resistance genes have had disappointing outcomes and/or require highly genotoxic m

188 Such disappointing outcomes clearly call for broadening the s

189 Disappointing outcomes in clinical trials aimed at augme

190 Disappointing outcomes of nano-sized formulations (nanof

191 which immune rejection contributes to these disappointing outcomes using an immunodeficient IL2 rece

192 istent atrial fibrillation (PersAF) have had disappointing outcomes, despite concerted clinical and r

193 systemic therapies, including taxanes, yield disappointing outcomes.

194 with the RXR ligand (rexinoid) have yielded disappointing outcomes.

195 er failure of those first-line therapies are disappointing overall, with many patients eventually req

196 d targeted therapy trials have thus far been disappointing owing to a lack of robust stratification m

197 ion methods of nanowire-like devices produce disappointing performance because of process-induced mat

198 Recent clinical setbacks and disappointing performance of preclinical compounds in an

199 wever, human trials with vitamin E have been disappointing, perhaps related to ineffective levels of

200 age of the term "DNA vaccines," however, the disappointing potency of the DNA vaccines in humans unde

201 outcomes of somatic cell transplants remain disappointing, presumably due to lack of appropriate sup

202 A major reason for disappointing progress of psychiatric diagnostics and no

203 th attendant inflated development costs) and disappointing progress.

204 ever, progression-free survival rates remain disappointing, ranging from 40% to 50%.

205 The disappointing recent failure of fluoroquinolone-containi

206 against specific tumors have so far produced disappointing results against ovarian cancer.

207 lipoprotein (LDL) in vitro and has displayed disappointing results against the onset and development

208 Despite this, programs have yielded disappointing results and can have unintended consequenc

209 therapy with rapamycin analogues has yielded disappointing results due in part to compensatory up-reg

210 ly responsive to chemotherapy, combined with disappointing results from a recent SCLC clinical trial

211 After disappointing results from all efficacy trials conducted

212 ossible cellular explanation contributing to disappointing results from anti-Abeta therapeutic trials

213 Disappointing results from most late-stage clinical tria

214 Disappointing results from recent trials of improved coo

215 diovascular disease paved the way to largely disappointing results from several large prevention tria

216 der in which conventional treatment leads to disappointing results in a proportion of patients.

217 DA-approved drug that has previously yielded disappointing results in clinical trials in patients wit

218 cause current pan-HDAC inhibitors have shown disappointing results in clinical trials of solid tumors

219 nation of why anti-EGFR therapies have shown disappointing results in clinical trials.

220 The disappointing results in humans should be taken as an op

221 with promising results in certain areas and disappointing results in others.

222 Some of these have yielded disappointing results in practice but are now of renewed

223 ion of the mismatch are also responsible for disappointing results in the application of perfusion-we

224 ation in immunologically fit individuals and disappointing results in the elderly and immunocompromis

225 t year, several promising approaches yielded disappointing results in the phase III setting (GVAX); n

226 t year, several promising approaches yielded disappointing results in the phase III setting (GVAX, sa

227 In contrast, oral agents have yielded disappointing results in the secondary prevention of acu

228 n infectious disease models but have yielded disappointing results in tumor models when tumor-associa

229 al limb ischemia all have contributed to the disappointing results of balloon angioplasty for complex

230 Despite the disappointing results of Explorer and Lunar trials, othe

231 This could explain the disappointing results of FGF-2 therapy in clinical trial

232 The lack of effective treatments, disappointing results of many HF randomized clinical tri

233 Angst over disappointing results of neuroprotection trials in Parki

234 trials, was then tempered by the subsequent disappointing results of randomized clinical trials.

235 e involving more diverse regimens, following disappointing results of retinoid monotherapy.

236 On the flip side, the disappointing results of rituximab in lupus nephritis pr

237 The disappointing results of the National Emphysema Treatmen

238 eart disease and may help explain the mostly disappointing results of this approach to date.

239 These disappointing results represent a policy failure within

240 These disappointing results stand in sharp contrast to estimat

241 ve been used in a small clinical trial, with disappointing results to date.

242 Disappointing results were announced for a number of lar

243 The disappointing results were attributed largely to poor ad

244 By contrast, disappointing results with antigen-based therapeutics hi

245 Unfortunately, there have been disappointing results with regard to improvement of tumo

246 Chemotherapy and radiation afford disappointing results, however, and novel therapies are

247 In light of these disappointing results, investigators have pursued altern

248 trials of glutamatergic modulators have had disappointing results, our growing understanding suggest

249 Despite disappointing results, two recent medication trials show

250 el mechanism-based treatments brought rather disappointing results, with low, if any, drug efficacy a

251 c therapy for ischemic heart disease has had disappointing results.

252 en evaluated in several clinical trials with disappointing results.

253 followed but were initially met with largely disappointing results.

254 dates, human trials have exclusively yielded disappointing results.

255 eradicate this viral reservoir have yielded disappointing results.

256 the myocardium using stem cells have yielded disappointing results.

257 mpts to improve adherence have often yielded disappointing results.

258 However, the clinical trials yielded disappointing results.

259 s of the inflammatory response, have yielded disappointing results.

260 y has been explored in myeloma patients with disappointing results.

261 ic strategies have so far yielded relatively disappointing results.

262 erapy for iliofemoral venous thrombosis with disappointing results.

263 w exceptions, empirical studies have yielded disappointing results.

264 ls with anticytokine therapies have produced disappointing results.

265 mmatory response, however, have thus far had disappointing results.

266 ion against virion proteins but have yielded disappointing results.

267 ter bodies but several times with unexpected disappointing results.

268 test this possibility, however, have yielded disappointing results.

269 performed for hemangiosarcoma (HAS) despite disappointing results.

270 ase (PD) have produced variable, but overall disappointing, results.

271 ted at tumor necrosis factor alpha have been disappointing so far, although preliminary studies with

272 ut their effect on clinical outcome has been disappointing so far, except for saphenous vein bypass g

273 ical trials for acute pancreatitis have been disappointing, so strategies that target and alter the b

274 While this disappointing state of affairs may suggest that plasma p

275 ease-modifying approaches have been thus far disappointing, steady advances are being made in the sym

276 in vitro, recent clinical trial results are disappointing, suggesting that MSC viability and/or func

277 Disappointing survival rates from out-of-hospital cardia

278 HCT service use increased over time, it was disappointing that the proportions ever testing and ever

279 past 7 years, it has been surprising, almost disappointing, that germline MCU deficiency in mice with

280 These findings may explain the disappointing therapeutic effect of targeting IL-17A in

281 es using single targeted therapies have been disappointing, therefore providing the impetus for novel

282 The results for other rTMS paradigms are disappointing thus far.

283 hase 1 and 2 clinical trials have been quite disappointing to date, and toxicities sometimes have bee

284 hibitors targeting individual RTKs have been disappointing to date.

285 cardioprotective signaling has been largely disappointing to date.

286 usable system lasts for years." It is indeed disappointing to discover that your data resources are n

287 xplain variation in population risk had been disappointing until the advent of technologies that assa

288 r prognostic accuracy of markers often prove disappointing when "discrimination" found between cancer

289 rials of antiangiogenic strategies have been disappointing when administered as single agents, such a

290 ise in some malignancies have generally been disappointing when applied to high-grade brain tumors su

291 ocyte transplantation for cirrhosis has been disappointing when compared with laboratory experience.

292 harmaceuticals targeting this class has been disappointing, where it has been a major problem to obta

293 clinical studies, outcomes are consistently disappointing with 5-year overall survival rates of ~10%

294 les for diagnostic purposes have been rather disappointing with respect to their clinical validity, i

295 e resection, 5-year survival rates have been disappointing, with about 50% of patients eventually suf

296 ndritic cell (DC)-based immunotherapy remain disappointing, with DCs often displaying a tenuous capac

297 n IIb/IIIa inhibition have been consistently disappointing, with evolving evidence of increased morta

298 of follow-up, longer-term results have been disappointing, with increased rates of device thrombosis

299 ed aimed at the PPTg, but outcomes have been disappointing, with little evidence that gait and postur

300 While numerous factors contributed to the disappointing yield, one factor was that essential genes